Action
Lipid peroxidation inhibitor

Status
RANTTAS-1 tested tirilazad, 6 mg/kg per day for 3 days. RANTTAS-1 was stopped after 660 patients had been randomized, because interim analysis suggested lack of efficacy. Phase III trial of higher dose (RANTTAS II) was stopped after 126 patients had been enrolled, when questions regarding safety emerged from a parallel study in Europe. "Tirilazad treatment was associated with an absolute reduction in mortality of 14% and an increase in the proportion of patients who were independent. . . The observed differences were not statistically significant." US trial in head trauma halted in 1994 because of concerns of excess mortality. Tirilazad has also been tested in spinal cord injury and subarachnoid hemorrhage.

Trial(s)
  = Ongoing
  = Completed

		High-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage - Part I.
		High-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage-Part II.
		Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage
		Randomized, double-blind, placebo-controlled trial of tirilazad mesylate in subarachnoid hemorrhage: cooperative study in North America
		Randomized, double-blind, placebo-controlled trial of tirilazad mesylate: a cooperative study in Europe, Australia, and New Zealand
	RANTTAS II	Randomized Trial of High Dose Tirilzad in Acute Stroke
	RANTTAS	Randomized Trial of Tirilazad Mesylate in Acute Stroke

UID: 38